Ensysce Biosciences EBITDA Growth & History (ENSC)
Ensysce Biosciences's calculated EBITDA was −$10.2M for fiscal 2025.
View full Ensysce Biosciences company overviewEnsysce Biosciences annual ebitda history
2020
2021
2022
2023
2024
2025
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$10.2M | −$3.5M | — |
| 2024 | 2024-12-31 | −$6.7M | $4.0M | — |
| 2023 | 2023-12-31 | −$10.7M | $13.5M | — |
| 2022 | 2022-12-31 | −$24.2M | −$4.4M | — |
| 2021 | 2021-12-31 | −$19.9M | −$18.3M | — |
| 2020 | 2020-12-31 | −$1.6M | — | — |
Ensysce Biosciences quarterly ebitda
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$2.6M | −$819,341 | — |
| Q1 2026 | 2026-03-31 | −$3.6M | −$1.6M | — |
| Q4 2025 | 2025-12-31 | −$2.8M | $801,183 | — |
| Q3 2025 | 2025-09-30 | −$3.7M | −$4.4M | — |
| Q2 2025 | 2025-06-30 | −$1.8M | $204,927 | — |
| Q1 2025 | 2025-03-31 | −$2.0M | −$124,548 | — |
| Q4 2024 | 2024-12-31 | −$3.6M | — | — |
| Q3 2024 | 2024-09-30 | $644,746 | — | — |
| Q2 2024 | 2024-06-30 | −$2.0M | — | — |
| Q1 2024 | 2024-03-31 | −$1.8M | — | — |
| Q4 2021 | 2021-12-31 | −$2.0M | — | — |
| Q3 2021 | 2021-09-30 | −$16.9M | −$16.5M | — |
| Q2 2021 | 2021-06-30 | −$412,567 | −$551,698 | — |
| Q1 2021 | 2021-03-31 | −$524,222 | — | — |
| Q3 2020 | 2020-09-30 | −$404,724 | — | — |
| Q2 2020 | 2020-06-30 | $139,131 | — | — |
Ensysce Biosciences ebitda trends
Over the last five fiscal years, Ensysce Biosciences's ebitda decreased from −$1.6M to −$10.2M, a change of −$8.6M. The latest reported quarter, Q2 2026, shows −$2.6M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ensysce Biosciences source filings ↗